A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

[1]  P. Seeman.  Glutamate and dopamine components in schizophrenia. , 2009, Journal of psychiatry & neuroscience : JPN.

[2]  A. Carlsson,et al.  The 'atypicality' of antipsychotics: a concept re-examined and re-defined , 2009, Nature Reviews Drug Discovery.

[3]  D. Bayliss,et al.  HCN1 Channel Subunits Are a Molecular Substrate for Hypnotic Actions of Ketamine , 2009, The Journal of Neuroscience.

[4]  S. Okuda,et al.  Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia , 2008, Pharmacology Biochemistry and Behavior.

[5]  S. Marder,et al.  Better pharmacotherapy for schizophrenia: What does the future hold? , 2008, Current psychiatry reports.

[6]  G. Winterer,et al.  The Molecular and Cellular Neurobiology of Nicotine Abuse in Schizophrenia , 2008, Pharmacopsychiatry.

[7]  J. Gold,et al.  Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.

[8]  J. Lieberman,et al.  Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. , 2008, The American journal of psychiatry.

[9]  J. Buccafusco,et al.  The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates , 2008, Psychopharmacology.

[10]  D. Goff,et al.  Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia , 2008, Psychopharmacology.

[11]  W. Hevers,et al.  Ketamine, But Not Phencyclidine, Selectively Modulates Cerebellar GABAA Receptors Containing α6 and δ Subunits , 2008, The Journal of Neuroscience.

[12]  M. Quik,et al.  Cotinine Selectively Activates a Subpopulation of α3/α6β2* Nicotinic Receptors in Monkey Striatum , 2008, Journal of Pharmacology and Experimental Therapeutics.

[13]  J. J. Chrobak,et al.  Revealing Past Memories: Proactive Interference and Ketamine-Induced Memory Deficits , 2008, The Journal of Neuroscience.

[14]  F. Nicoletti,et al.  The Use of Knock-Out Mice Unravels Distinct Roles for mGlu2 and mGlu3 Metabotropic Glutamate Receptors in Mechanisms of Neurodegeneration/Neuroprotection , 2007, The Journal of Neuroscience.

[15]  R. Papke,et al.  The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery , 2007, Journal of neurochemistry.

[16]  J. Buccafusco,et al.  Disconnection between activation and desensitization of autonomic nicotinic receptors by nicotine and cotinine , 2007, Neuroscience Letters.

[17]  R. Paz,et al.  Increased expression of activity-dependent genes in cerebellar glutamatergic neurons of patients with schizophrenia. , 2006, The American journal of psychiatry.

[18]  C. Morgan,et al.  Acute and chronic effects of ketamine upon human memory: a review , 2006, Psychopharmacology.

[19]  J. Buccafusco,et al.  Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. , 2006, CNS drug reviews.

[20]  Robert Freedman,et al.  Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia , 2006 .

[21]  D. S. Fokkema,et al.  Dose–response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity , 2006, Brain Research Bulletin.

[22]  Robert C. Smith,et al.  Effects of Nicotine Nasal Spray on Cognitive Function in Schizophrenia , 2006, Neuropsychopharmacology.

[23]  J. Buccafusco,et al.  Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. , 2005, Trends in pharmacological sciences.

[24]  R. Baldessarini,et al.  Modern antipsychotic drugs: a critical overview , 2005, Canadian Medical Association Journal.

[25]  R. Heinrichs.  The primacy of cognition in schizophrenia. , 2005, The American psychologist.

[26]  M. Kurtz.  Neurocognitive impairment across the lifespan in schizophrenia: an update , 2005, Schizophrenia Research.

[27]  Paul J. Harrison,et al.  Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons , 2005, Schizophrenia Research.

[28]  E. Stip,et al.  On the trail of a cognitive enhancer for the treatment of schizophrenia , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[29]  Robert Freedman,et al.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia , 2004, Psychopharmacology.

[30]  Patricia S. Goldman-Rakic,et al.  Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia , 2004, Psychopharmacology.

[31]  N. Andreasen.  Schizophrenia: the fundamental questions , 2000, Brain Research Reviews.

[32]  L. Dwoskin,et al.  (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. , 1999, The Journal of pharmacology and experimental therapeutics.

[33]  R. Elliott,et al.  Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. , 1998, Neurotoxicology and teratology.

[34]  Philip D. Harvey,et al.  Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. , 1998, The American journal of psychiatry.

[35]  L. Dwoskin,et al.  Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. , 1997, Biochemical pharmacology.

[36]  R. Papke,et al.  3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner , 1997, Brain Research.

[37]  D. Hatsukami,et al.  Safety of Cotinine in Humans: Physiologic, Subjective, and Cognitive Effects , 1997, Pharmacology Biochemistry and Behavior.

[38]  A. Maurset,et al.  Interaction of the chiral forms of ketamine with opioid, phencyclidine, σ and muscarinic receptors , 1995 .

[39]  C. Galletly.  Recent advances in treating cognitive impairment in schizophrenia , 2008, Psychopharmacology.

[40]  Martin Sarter,et al.  A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia , 2008, Psychopharmacology.

[41]  J. Buccafusco.  Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders. , 2008, Journal of Alzheimer's disease : JAD.

[42]  A. Olincy,et al.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. , 2007, Biochemical pharmacology.

[43]  R. Freedman,et al.  Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. , 2006, Archives of general psychiatry.

[44]  J. Lieberman,et al.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.

[45]  M. Novak,et al.  Environmental enrichment for nonhuman primates: theory and application. , 2005, ILAR journal.

[46]  C. Elwin,et al.  The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers , 2004, European Journal of Clinical Pharmacology.

[47]  D. Braff,et al.  Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? , 2000, Schizophrenia bulletin.

[48]  S. Bergman.  Ketamine: review of its pharmacology and its use in pediatric anesthesia. , 1999, Anesthesia progress.

[49]  Bergman Sa.  Ketamine: review of its pharmacology and its use in pediatric anesthesia. , 1999 .

[50]  E. Callaway,et al.  Effects of cotinine on information processing in nonsmokers , 1998, Psychopharmacology.

[51]  W. J. Jackson,et al.  Functional Characterization of the Novel Neuronal Nicotinic Acetylcholine Receptor Ligand GTS-21 In Vitro and In Vivo , 1997, Pharmacology Biochemistry and Behavior.

[52]  I. Oye,et al.  Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. , 1995, Pharmacology & toxicology.